Latest Content

Real-world ASCO data link GLP-1 drugs to markedly longer survival across common cancers, raising new questions on mechanism and trials.

Patients with narcolepsy type 1 reported high disease burden, including chronic symptoms like hallucinations, sleep paralysis, and difficulty concentrating.

A pooled nonrandomized trial of AAVrh.10hFXN across 17 patients showed reduced LVMI and lower high-sensitivity troponin I levels at all 3 dose cohorts.

Late-breaking abstracts presented during the Sleep 2026 Annual Meeting provided new data on how the time of year could change sleep duration and the efficacy of low-sodium oxybate.

Cardinal Health hires ex-FCS leader Nathan Walcker to drive The Specialty Alliance's growth, including managed services in gastroenterology and urology.

Tarik Asselah, MD, PhD, explains why HDV RNA suppression deepened through 2 years with tobevibart plus elebsiran.

This new analysis offers some of the most rigorous real-world data to guide treatment decisions for TP53 wild-type chronic lymphocytic leukemia.

The FDA's first new sunscreen ingredient approved in nearly 3 decades is set to reshape the US market. Here is what dermatologists need to know.

The American Heart Association’s Life’s Essential 8 indicates that the key to a healthy heart is through the treatment of sleep, including in obstructive sleep apnea (OSA) and narcolepsy.